Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$4.8 - $7.25 $2.54 Million - $3.83 Million
-528,169 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$4.57 - $7.18 $2.41 Million - $3.79 Million
528,169 New
528,169 $2.97 Million
Q3 2020

Nov 16, 2020

SELL
$3.85 - $28.47 $241,067 - $1.78 Million
-62,615 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$16.01 - $34.69 $1 Million - $2.17 Million
62,615 New
62,615 $1.8 Million

About Satsuma Pharmaceuticals, Inc.


  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.